Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Medtronic
Harvard Business School
Colorcon
Moodys

Last Updated: August 15, 2022

Investigational Drug Information for Crenezumab


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Crenezumab?

Crenezumab is an investigational drug.

There have been 8 clinical trials for Crenezumab. The most recent clinical trial was a Phase 2 trial, which was initiated on March 29th 2017.

The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are Genentech, Inc., Hoffmann-La Roche, and National Institute on Aging (NIA).

There are eleven US patents protecting this investigational drug and eighty-four international patents.

Recent Clinical Trials for Crenezumab
TitleSponsorPhase
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseBanner Alzheimer's InstitutePhase 2
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseNational Institute on Aging (NIA)Phase 2
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseGenentech, Inc.Phase 2

See all Crenezumab clinical trials

Clinical Trial Summary for Crenezumab

Top disease conditions for Crenezumab
Top clinical trial sponsors for Crenezumab

See all Crenezumab clinical trials

US Patents for Crenezumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Crenezumab See Plans and Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) See Plans and Pricing
Crenezumab See Plans and Pricing Bispecific chimeric antigen receptors and methods of use thereof to treat cancer Seattle Children's Hospital (Seattle, WA) See Plans and Pricing
Crenezumab See Plans and Pricing Compositions comprising purified anti-abeta monoclonal antibodies GENENTECH, INC. (South San Francisco, CA) See Plans and Pricing
Crenezumab See Plans and Pricing Intranasal administration of guanidinylated aminoglycosides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Crenezumab

Drugname Country Document Number Estimated Expiration Related US Patent
Crenezumab Australia AU2013220749 2032-02-15 See Plans and Pricing
Crenezumab Brazil BR112014019627 2032-02-15 See Plans and Pricing
Crenezumab Canada CA2862476 2032-02-15 See Plans and Pricing
Crenezumab China CN104114705 2032-02-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Medtronic
Harvard Business School
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.